BioCentury
ARTICLE | Clinical News

Genetic Immunity, Virostatics report HIV data

July 19, 2010 11:48 PM UTC

Genetic Immunity LLC (McLean, Va.) and Virostatics s.r.l. (Sassari, Italy) both reported HIV data at the International AIDS Conference in Vienna. Genetic Immunity's DermaVir Patch significantly reduced HIV viral load from baseline to week 24 by 0.5 log10 copies/mL compared to placebo in a Phase II trial. The double-blind, dose-ranging trial enrolled 36 treatment-naive patients. DermaVir is a synthetic plasmid DNA-containing vaccine administered topically by the dendritic cell-targeting DermaPrep transdermal delivery device. ...